Literature DB >> 9724022

Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene.

R T Turner1, G L Evans, J P Sluka, M D Adrian, H U Bryant, C H Turner, M Sato.   

Abstract

The substituted triphenylethylene antiestrogen clomiphene (CLO) prevents cancellous bone loss in ovariectomized (OVX'd) rats. However, CLO is a mixture of two stereoisomers, enclomiphene (ENC) and zuclomiphene (ZUC), which have distinctly different activities on reproductive tissues and tumor cells. The purpose of the present dose response study was to determine the effects of ENC and ZUC on nonreproductive estrogen target tissues. These studies were performed in 7-month-old female rats with moderate cancellous osteopenia that was established by ovariectomizing rats 1 month before initiating treatment. OVX resulted in increases in body weight, serum cholesterol, endocortical resorption, and indices of cancellous bone turnover, as well as decreases in uterine weight, uterine epithelial cell height, bone mineral density, bone strength, and cancellous bone area. Estrogen treatment for 3 months restored body weight, uterine histology, dynamic bone measurements, and osteoblast and osteoclast surfaces in OVX'd rats to the levels found in the age-matched sham-operated rats. In contrast, estrogen only partially restored cancellous bone volume and uterine weight, and it reduced serum cholesterol to subnormal values. CLO was a weak estrogen agonist on uterine measurements and a much more potent agonist on body weight, serum cholesterol, and dynamic bone measurements. CLO increased trabecular thickness in osteopenic rats and was the most effective treatment in improving cancellous bone volume and architecture. ZUC was a potent estrogen agonist on all tissues investigated and had dose-dependent effects. In contrast, ENC had dose-dependent effects on most measurements similar to CLO and decreased the uterotrophic effects of ZUC. It is concluded that ENC antagonizes the estrogenic effects of ZUC on the uterus but that the beneficial effects of CLO on nonreproductive tissues in OVX'd rats is conferred by both isomers. Furthermore, the combined actions of the two isomers on bone volume and architecture were more beneficial than either isomer given alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724022     DOI: 10.1210/endo.139.9.6177

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.

Authors:  Zeljka Korade; Hye-Young H Kim; Keri A Tallman; Wei Liu; Katalin Koczok; Istvan Balogh; Libin Xu; Karoly Mirnics; Ned A Porter
Journal:  J Med Chem       Date:  2016-01-29       Impact factor: 7.446

3.  TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro.

Authors:  Malayannan Subramaniam; Genevieve Gorny; Steven A Johnsen; David G Monroe; Glenda L Evans; Daniel G Fraser; David J Rickard; Kay Rasmussen; Jan M A van Deursen; Russell T Turner; Merry Jo Oursler; Thomas C Spelsberg
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

4.  Twelve months of voluntary heavy alcohol consumption in male rhesus macaques suppresses intracortical bone remodeling.

Authors:  Gino W Gaddini; Kathleen A Grant; Andrew Woodall; Cara Stull; Gianni F Maddalozzo; Bo Zhang; Russell T Turner; Urszula T Iwaniec
Journal:  Bone       Date:  2014-11-07       Impact factor: 4.398

5.  Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice.

Authors:  Kristen E Govoni; Jon E Wergedal; Robert B Chadwick; Apurva K Srivastava; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-23       Impact factor: 4.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.